Nearly 87% of patients who underwent robot-assisted radical prostatectomy had no disease recurrence after 5 years, according to a recent multicenter study.
Nearly 87% of patients who underwent robot-assisted radical prostatectomy had no disease recurrence after 5 years, according to a recent multicenter study.
Mani Menon, MD, of Henry Ford Hospital’s Vattikuti Urology Institute, Detroit, and co-authors studied 1,384 men (mean age, 60 years) with moderately aggressive prostate cancer who underwent robot-assisted radical prostatectomy between September 2001 and May 2005.
The patients were checked for recurrence every 3 months during the first year after surgery, twice during the second year, then annually. A median follow-up of 5 years was used for the study.
The fact that deaths from prostate cancer occurred in only one of 1,000 patients per year of follow-up should provide a strong endorsement of the curative role of radical prostatectomy for patients with localized disease treated in the contemporary era, say the authors.
"With 5-year actuarial biochemical recurrence-free survival outcomes of 86.6%, robot-assisted radical prostatectomy appears to confer effective 5-year prostate cancer control," the authors wrote.
Results from the study were published online in European Urology (2010; 58:e53-e62).
From evidence to practice: Dr. Makarov discusses implementation science in urology
July 25th 2024“What our major contribution is, I think as urologists doing implementation science, is determining the important questions, which we are particularly well-suited to do because we're taking care of the patients,” says Danil V. Makarov, MD, MHS.
Phase 1B trial to evaluate relugolix and enzalutamide in high-risk prostate cancer
July 24th 2024"Going forward after this study, we hope to be able to expand and potentially look at patients undergoing either surgery or radiation therapy, and really try to determine the potential benefit," says Kelly L. Stratton, MD, FACS.